Predicting Risk of Cardiovascular Disease EVENTs (PREVENT™) Calculator
Predicts 10- and 30-year risk of CVD and CVD subtypes in patients aged 30-79 without known CVD.
Creator
American Heart Association PREVENT™️ TeamInstructions
This tool updates and replaces the AHA/ACC Pooled Cohort Equations published in 2014.
Intended for adults aged 30-79 years who do not have known cardiovascular disease.
PREVENT™️ estimates 10-year and 30-year risk of:
Total cardiovascular disease (CVD)
Atherosclerotic cardiovascular disease (ASCVD)
Heart failure
Coronary artery disease (CAD)
Stroke
The 30-year estimates apply to adults aged 30–59 years.
Optional variables include urine albumin-to-creatinine ratio, HbA1c and a social deprivation index (US SIP code-based) to refine the estimate when they are available.
Patient characteristics
Developed by the American Heart Association in 2023, the Predicting Risk of Cardiovascular Disease EVENTs (PREVENT) equations estimate 10-year and 30-year risk for total cardiovascular disease (CVD), including atherosclerotic CVD (ASCVD) and heart failure (HF). It is the first risk tool to combine cardiovascular, kidney, and metabolic health measures to guide primary prevention-focused treatment decisions.
The equations were derived and validated using data from over 6.5 million U.S. adults across multiple datasets, and they are validated for adults ages 30–79 years without known CVD.
The PREVENT calculator, based on the PREVENT equations, uses required clinical information to estimate CVD risk. Three optional predictors, urine albumin-creatinine ratio (UACR), hemoglobin A1c (HbA1c), and social deprivation index (SDI), can further personalize risk estimates.
The PREVENT calculator provide separate 10-year and 30-year estimates for total CVD (PREVENT-CVD), ASCVD (PREVENT-ASCVD), and HF (PREVENT-HF). The default display is PREVENT-CVD, but each outcome can be selected individually. Because ASCVD and HF are modeled independently, their combined risk may exceed the total CVD estimate.
Patient Eligibility for the PREVENT Equations
Use the PREVENT equations for adults* ages 30–79 without known CVD.
Do not use the PREVENT equations for adults with known CVD, evidence of severe subclinical CVD (e.g., left ventricular ejection fraction <40%, coronary artery calcium ≥300), positive genetic testing for a variant known to be pathogenic or for an inherited cardiovascular condition, end-stage kidney disease, or limited life expectancy (<1 year).
*Out-of-range values should be managed as clinically indicated. Risk can still be estimated with the closest in-range value but may represent an over- or under-estimate.
All questions & possible results
Patient characteristics
Sex
Select one option:
- Male
- Female
Age
A number between 30 and 79 (whole numbers), in years.
Measurements
Height and weight are used to calculate the BMI.
BMI is only used as a predictor for the heart failure risk calculation.
Caution: BMIs <18.5 kg/m² and ≥40.0 kg/m² were excluded in the derivation study.
Systolic blood pressure
A number between 90 and 200 (whole numbers), in mm Hg.
Height
A number between 120 and 220, in cm or in.
Weight
A number between 30 and 250, in kg or lbs.
Laboratory values
Total cholesterol
Normal ranges
150-200 mg/dL
3.9-5.2 mmol/L
A number between 130 and 320, in mg/dL or mmol/L.
HDL cholesterol
Normal ranges
20-60 mg/dL
0.52-1.55 mmol/L
A number between 20 and 100, in mg/dL or mmol/L.
eGFR
CKD-EPI Equations for Glomerular Filtration Rate (GFR) calculator
Normal range: 90-100
A number between 15 and 140, in mL/min/1.73 m².
Medical history and treatment
Diabetes
Select one option:
- No
- Yes
Current smoker
Select one option:
- No
- Yes
Taking anti-hypertensive medication
Select one option:
- No
- Yes
Taking a statin
Select one option:
- No
- Yes
Optional predictors
Which optional predictors are available?
Urine albumin/creatinine ratio, HbA1c, and social deprivation index (SDI) are optional predictors that can be included for more personalized risk assessment.
urine albumin-creatinine ratio (uACR) is Indicated for those patients with chronic kidney disease, diabetes, or hypertension.
HbA1c is Indicated for those with a history of diabetes, prediabetes, or gestational diabetes, and for those who are overweight or obese.
Social deprivation index is assigned based on US zip code. Derived and validated using US-based cohorts, which limits generalizability outside the United States.
Select one option:
- None (base model only)
- uACR only
- HbA1c only
- Social Deprivation Index only
- All three (uACR, HbA1c and Social Deprivation Index)
uACR
The minimum urine albumin-creatinine ratio (uACR) value accepted by the model is 0.1mg/g. If your laboratory reports a value lower than this, enter 0.1mg/g.
Indicated for those patients with chronic kidney disease, diabetes, or hypertension.
Normal range: 0.1-30 mg/g
A number between 0.1 and 25000, in mg/g.
HbA1c
Indicated for those with a history of diabetes, prediabetes, or gestational diabetes, and for those who are overweight or obese.
Normal range: 4-5.6%
A number between 3 and 15, in %.
Social Deprivation Index
Social deprivation index is assigned based on US zip code.
A number between 4 and 99999 (whole numbers).
Possible results
10-year ASCVD risk category: LOW (<3%) - Male Base Model
Risk thresholds used with PREVENT™️ (e.g., 3%–10%) are evolving and not yet fully validated for management decisions.
Primary Prevention
The 2026 ACC/AHA Guideline uses the following risk categories and recommended primary prevention measures (based on 10-year ASCVD risk):
Health behavior counseling.
If LDL-C 160–189 mg/dL or 30-year ASCVD risk is ≥10%, consider moderate-intensity statin therapy.
Lipid-lowering Therapy
The following groups should receive lipid-lowering therapy regardless of calculated risk:
Established clinical ASCVD.
LDL-C ≥190 mg/dL.
Aged 40–75 with diabetes, chronic kidney disease stage 3 or higher, or HIV on stable combination antiretroviral therapy.
Hypertension
The 2025 AHA/ACC Guideline recommends the following hypertension management (based on 10-year total CVD risk):
BP ≥130/80 mmHg:
Treat if risk estimate ≥7.5%, or if clinical CVD, diabetes, or CKD is present.
If risk estimate is <7.5%, try lifestyle modification for 3–6 months first; start medication if BP remains elevated.
BP ≥140/90 mmHg: Treat all adults regardless of CVD risk estimate.
Risk estimates should be interpreted in the context of:
Patient comorbidities (e.g., diabetes, CKD, obesity).
Risk-enhancing factors (e.g., family history, lipoprotein(a), inflammatory conditions, coronary artery calcium score).
Patient preferences.
Treatment goals.
Based on the 10-year PREVENT-ASCVD estimate for the model that matches the optional predictors entered. Category cutoffs are those reported for the 2026 ACC/AHA dyslipidemia guideline by secondary summaries; confirm against the guideline text before use.
10-year ASCVD risk category: LOW (<3%) - Male Full Model
Risk thresholds used with PREVENT™️ (e.g., 3%–10%) are evolving and not yet fully validated for management decisions.
Primary Prevention
The 2026 ACC/AHA Guideline uses the following risk categories and recommended primary prevention measures (based on 10-year ASCVD risk):
Health behavior counseling.
If LDL-C 160–189 mg/dL or 30-year ASCVD risk is ≥10%, consider moderate-intensity statin therapy.
Lipid-lowering Therapy
The following groups should receive lipid-lowering therapy regardless of calculated risk:
Established clinical ASCVD.
LDL-C ≥190 mg/dL.
Aged 40–75 with diabetes, chronic kidney disease stage 3 or higher, or HIV on stable combination antiretroviral therapy.
Hypertension
The 2025 AHA/ACC Guideline recommends the following hypertension management (based on 10-year total CVD risk):
BP ≥130/80 mmHg:
Treat if risk estimate ≥7.5%, or if clinical CVD, diabetes, or CKD is present.
If risk estimate is <7.5%, try lifestyle modification for 3–6 months first; start medication if BP remains elevated.
BP ≥140/90 mmHg: Treat all adults regardless of CVD risk estimate.
Risk estimates should be interpreted in the context of:
Patient comorbidities (e.g., diabetes, CKD, obesity).
Risk-enhancing factors (e.g., family history, lipoprotein(a), inflammatory conditions, coronary artery calcium score).
Patient preferences.
Treatment goals.
Based on the 10-year PREVENT-ASCVD estimate for the model that matches the optional predictors entered. Category cutoffs are those reported for the 2026 ACC/AHA dyslipidemia guideline by secondary summaries; confirm against the guideline text before use.
10-year ASCVD risk category: LOW (<3%) - Female Full Model
Risk thresholds used with PREVENT™️ (e.g., 3%–10%) are evolving and not yet fully validated for management decisions.
Primary Prevention
The 2026 ACC/AHA Guideline uses the following risk categories and recommended primary prevention measures (based on 10-year ASCVD risk):
Health behavior counseling.
If LDL-C 160–189 mg/dL or 30-year ASCVD risk is ≥10%, consider moderate-intensity statin therapy.
Lipid-lowering Therapy
The following groups should receive lipid-lowering therapy regardless of calculated risk:
Established clinical ASCVD.
LDL-C ≥190 mg/dL.
Aged 40–75 with diabetes, chronic kidney disease stage 3 or higher, or HIV on stable combination antiretroviral therapy.
Hypertension
The 2025 AHA/ACC Guideline recommends the following hypertension management (based on 10-year total CVD risk):
BP ≥130/80 mmHg:
Treat if risk estimate ≥7.5%, or if clinical CVD, diabetes, or CKD is present.
If risk estimate is <7.5%, try lifestyle modification for 3–6 months first; start medication if BP remains elevated.
BP ≥140/90 mmHg: Treat all adults regardless of CVD risk estimate.
Risk estimates should be interpreted in the context of:
Patient comorbidities (e.g., diabetes, CKD, obesity).
Risk-enhancing factors (e.g., family history, lipoprotein(a), inflammatory conditions, coronary artery calcium score).
Patient preferences.
Treatment goals.
Based on the 10-year PREVENT-ASCVD estimate for the model that matches the optional predictors entered. Category cutoffs are those reported for the 2026 ACC/AHA dyslipidemia guideline by secondary summaries; confirm against the guideline text before use.
10-year ASCVD risk category: LOW (<3%) - Female Base + HbA1c Model
Risk thresholds used with PREVENT™️ (e.g., 3%–10%) are evolving and not yet fully validated for management decisions.
Primary Prevention
The 2026 ACC/AHA Guideline uses the following risk categories and recommended primary prevention measures (based on 10-year ASCVD risk):
Health behavior counseling.
If LDL-C 160–189 mg/dL or 30-year ASCVD risk is ≥10%, consider moderate-intensity statin therapy.
Lipid-lowering Therapy
The following groups should receive lipid-lowering therapy regardless of calculated risk:
Established clinical ASCVD.
LDL-C ≥190 mg/dL.
Aged 40–75 with diabetes, chronic kidney disease stage 3 or higher, or HIV on stable combination antiretroviral therapy.
Hypertension
The 2025 AHA/ACC Guideline recommends the following hypertension management (based on 10-year total CVD risk):
BP ≥130/80 mmHg:
Treat if risk estimate ≥7.5%, or if clinical CVD, diabetes, or CKD is present.
If risk estimate is <7.5%, try lifestyle modification for 3–6 months first; start medication if BP remains elevated.
BP ≥140/90 mmHg: Treat all adults regardless of CVD risk estimate.
Risk estimates should be interpreted in the context of:
Patient comorbidities (e.g., diabetes, CKD, obesity).
Risk-enhancing factors (e.g., family history, lipoprotein(a), inflammatory conditions, coronary artery calcium score).
Patient preferences.
Treatment goals.
Based on the 10-year PREVENT-ASCVD estimate for the model that matches the optional predictors entered. Category cutoffs are those reported for the 2026 ACC/AHA dyslipidemia guideline by secondary summaries; confirm against the guideline text before use.
10-year ASCVD risk category: LOW (<3%) - Male Base + uACR Model
Risk thresholds used with PREVENT™️ (e.g., 3%–10%) are evolving and not yet fully validated for management decisions.
Primary Prevention
The 2026 ACC/AHA Guideline uses the following risk categories and recommended primary prevention measures (based on 10-year ASCVD risk):
Health behavior counseling.
If LDL-C 160–189 mg/dL or 30-year ASCVD risk is ≥10%, consider moderate-intensity statin therapy.
Lipid-lowering Therapy
The following groups should receive lipid-lowering therapy regardless of calculated risk:
Established clinical ASCVD.
LDL-C ≥190 mg/dL.
Aged 40–75 with diabetes, chronic kidney disease stage 3 or higher, or HIV on stable combination antiretroviral therapy.
Hypertension
The 2025 AHA/ACC Guideline recommends the following hypertension management (based on 10-year total CVD risk):
BP ≥130/80 mmHg:
Treat if risk estimate ≥7.5%, or if clinical CVD, diabetes, or CKD is present.
If risk estimate is <7.5%, try lifestyle modification for 3–6 months first; start medication if BP remains elevated.
BP ≥140/90 mmHg: Treat all adults regardless of CVD risk estimate.
Risk estimates should be interpreted in the context of:
Patient comorbidities (e.g., diabetes, CKD, obesity).
Risk-enhancing factors (e.g., family history, lipoprotein(a), inflammatory conditions, coronary artery calcium score).
Patient preferences.
Treatment goals.
Based on the 10-year PREVENT-ASCVD estimate for the model that matches the optional predictors entered. Category cutoffs are those reported for the 2026 ACC/AHA dyslipidemia guideline by secondary summaries; confirm against the guideline text before use.
10-year ASCVD risk category: LOW (<3%) - Female Base + uACR Model
Risk thresholds used with PREVENT™️ (e.g., 3%–10%) are evolving and not yet fully validated for management decisions.
Primary Prevention
The 2026 ACC/AHA Guideline uses the following risk categories and recommended primary prevention measures (based on 10-year ASCVD risk):
Health behavior counseling.
If LDL-C 160–189 mg/dL or 30-year ASCVD risk is ≥10%, consider moderate-intensity statin therapy.
Lipid-lowering Therapy
The following groups should receive lipid-lowering therapy regardless of calculated risk:
Established clinical ASCVD.
LDL-C ≥190 mg/dL.
Aged 40–75 with diabetes, chronic kidney disease stage 3 or higher, or HIV on stable combination antiretroviral therapy.
Hypertension
The 2025 AHA/ACC Guideline recommends the following hypertension management (based on 10-year total CVD risk):
BP ≥130/80 mmHg:
Treat if risk estimate ≥7.5%, or if clinical CVD, diabetes, or CKD is present.
If risk estimate is <7.5%, try lifestyle modification for 3–6 months first; start medication if BP remains elevated.
BP ≥140/90 mmHg: Treat all adults regardless of CVD risk estimate.
Risk estimates should be interpreted in the context of:
Patient comorbidities (e.g., diabetes, CKD, obesity).
Risk-enhancing factors (e.g., family history, lipoprotein(a), inflammatory conditions, coronary artery calcium score).
Patient preferences.
Treatment goals.
Based on the 10-year PREVENT-ASCVD estimate for the model that matches the optional predictors entered. Category cutoffs are those reported for the 2026 ACC/AHA dyslipidemia guideline by secondary summaries; confirm against the guideline text before use.
10-year ASCVD risk category: LOW (<3%) - Female Base + SDI Model
Risk thresholds used with PREVENT™️ (e.g., 3%–10%) are evolving and not yet fully validated for management decisions.
Primary Prevention
The 2026 ACC/AHA Guideline uses the following risk categories and recommended primary prevention measures (based on 10-year ASCVD risk):
Health behavior counseling.
If LDL-C 160–189 mg/dL or 30-year ASCVD risk is ≥10%, consider moderate-intensity statin therapy.
Lipid-lowering Therapy
The following groups should receive lipid-lowering therapy regardless of calculated risk:
Established clinical ASCVD.
LDL-C ≥190 mg/dL.
Aged 40–75 with diabetes, chronic kidney disease stage 3 or higher, or HIV on stable combination antiretroviral therapy.
Hypertension
The 2025 AHA/ACC Guideline recommends the following hypertension management (based on 10-year total CVD risk):
BP ≥130/80 mmHg:
Treat if risk estimate ≥7.5%, or if clinical CVD, diabetes, or CKD is present.
If risk estimate is <7.5%, try lifestyle modification for 3–6 months first; start medication if BP remains elevated.
BP ≥140/90 mmHg: Treat all adults regardless of CVD risk estimate.
Risk estimates should be interpreted in the context of:
Patient comorbidities (e.g., diabetes, CKD, obesity).
Risk-enhancing factors (e.g., family history, lipoprotein(a), inflammatory conditions, coronary artery calcium score).
Patient preferences.
Treatment goals.
Based on the 10-year PREVENT-ASCVD estimate for the model that matches the optional predictors entered. Category cutoffs are those reported for the 2026 ACC/AHA dyslipidemia guideline by secondary summaries; confirm against the guideline text before use.
10-year ASCVD risk category: LOW (<3%) - Male Base + SDI Model
Risk thresholds used with PREVENT™️ (e.g., 3%–10%) are evolving and not yet fully validated for management decisions.
Primary Prevention
The 2026 ACC/AHA Guideline uses the following risk categories and recommended primary prevention measures (based on 10-year ASCVD risk):
Health behavior counseling.
If LDL-C 160–189 mg/dL or 30-year ASCVD risk is ≥10%, consider moderate-intensity statin therapy.
Lipid-lowering Therapy
The following groups should receive lipid-lowering therapy regardless of calculated risk:
Established clinical ASCVD.
LDL-C ≥190 mg/dL.
Aged 40–75 with diabetes, chronic kidney disease stage 3 or higher, or HIV on stable combination antiretroviral therapy.
Hypertension
The 2025 AHA/ACC Guideline recommends the following hypertension management (based on 10-year total CVD risk):
BP ≥130/80 mmHg:
Treat if risk estimate ≥7.5%, or if clinical CVD, diabetes, or CKD is present.
If risk estimate is <7.5%, try lifestyle modification for 3–6 months first; start medication if BP remains elevated.
BP ≥140/90 mmHg: Treat all adults regardless of CVD risk estimate.
Risk estimates should be interpreted in the context of:
Patient comorbidities (e.g., diabetes, CKD, obesity).
Risk-enhancing factors (e.g., family history, lipoprotein(a), inflammatory conditions, coronary artery calcium score).
Patient preferences.
Treatment goals.
Based on the 10-year PREVENT-ASCVD estimate for the model that matches the optional predictors entered. Category cutoffs are those reported for the 2026 ACC/AHA dyslipidemia guideline by secondary summaries; confirm against the guideline text before use.
10-year ASCVD risk category: BORDERLINE (3% to <5%) - Male Base Model
Risk thresholds used with PREVENT™️ (e.g., 3%–10%) are evolving and not yet fully validated for management decisions.
Primary Prevention
The 2026 ACC/AHA Guideline uses the following risk categories and recommended primary prevention measures (based on 10-year ASCVD risk):
Health behavior counseling.
Discuss risk-benefit of pharmacotherapy and weigh risk enhancing factors (e.g., family history, lipoprotein(a), inflammatory conditions, coronary artery calcium score) within a framework of shared decision-making.
If moderate-intensity statin therapy is initiated, target a ≥30% LDL-C reduction with a goal of LDL-C <100 mg/dL and non-HDL-C <130 mg/dL.
Consider coronary artery calcium (CAC) test.
Lipid-lowering Therapy
The following groups should receive lipid-lowering therapy regardless of calculated risk:
Established clinical ASCVD.
LDL-C ≥190 mg/dL.
Aged 40–75 with diabetes, chronic kidney disease stage 3 or higher, or HIV on stable combination antiretroviral therapy.
Hypertension
The 2025 AHA/ACC Guideline recommends the following hypertension management (based on 10-year total CVD risk):
BP ≥130/80 mmHg:
Treat if risk estimate ≥7.5%, or if clinical CVD, diabetes, or CKD is present.
If risk estimate is <7.5%, try lifestyle modification for 3–6 months first; start medication if BP remains elevated.
BP ≥140/90 mmHg: Treat all adults regardless of CVD risk estimate.
Risk estimates should be interpreted in the context of:
Patient comorbidities (e.g., diabetes, CKD, obesity).
Risk-enhancing factors (e.g., family history, lipoprotein(a), inflammatory conditions, coronary artery calcium score).
Patient preferences.
Treatment goals.
Based on the 10-year PREVENT-ASCVD estimate for the model that matches the optional predictors entered. Category cutoffs are those reported for the 2026 ACC/AHA dyslipidemia guideline by secondary summaries; confirm against the guideline text before use.
30-year heart failure risk, base model (female)
BMI is only used as a predictor for the heart failure risk calculation.
BMIs outside the studied range of <18.5 kg/m² and ≥40.0 kg/m² were excluded in the derivation study.
30-year heart failure risk, base model (male)
BMI is only used as a predictor for the heart failure risk calculation.
BMIs outside the studied range of <18.5 kg/m² and ≥40.0 kg/m² were excluded in the derivation study.
30-year heart failure risk, base + uACR model (female)
BMI is only used as a predictor for the heart failure risk calculation.
BMIs outside the studied range of <18.5 kg/m² and ≥40.0 kg/m² were excluded in the derivation study.
30-year heart failure risk, base + uACR model (male)
BMI is only used as a predictor for the heart failure risk calculation.
BMIs outside the studied range of <18.5 kg/m² and ≥40.0 kg/m² were excluded in the derivation study.
30-year heart failure risk, base + HbA1c model (female)
BMI is only used as a predictor for the heart failure risk calculation.
BMIs outside the studied range of <18.5 kg/m² and ≥40.0 kg/m² were excluded in the derivation study.
30-year heart failure risk, base + HbA1c model (male)
BMI is only used as a predictor for the heart failure risk calculation.
BMIs outside the studied range of <18.5 kg/m² and ≥40.0 kg/m² were excluded in the derivation study.
30-year heart failure risk, base + Social Deprivation Index model (female)
BMI is only used as a predictor for the heart failure risk calculation.
BMIs outside the studied range of <18.5 kg/m² and ≥40.0 kg/m² were excluded in the derivation study.
30-year heart failure risk, base + Social Deprivation Index model (male)
BMI is only used as a predictor for the heart failure risk calculation.
BMIs outside the studied range of <18.5 kg/m² and ≥40.0 kg/m² were excluded in the derivation study.
10-year ASCVD risk category: BORDERLINE (3% to <5%) - Male Full Model
Risk thresholds used with PREVENT™️ (e.g., 3%–10%) are evolving and not yet fully validated for management decisions.
Primary Prevention
The 2026 ACC/AHA Guideline uses the following risk categories and recommended primary prevention measures (based on 10-year ASCVD risk):
Health behavior counseling.
Discuss risk-benefit of pharmacotherapy and weigh risk enhancing factors (e.g., family history, lipoprotein(a), inflammatory conditions, coronary artery calcium score) within a framework of shared decision-making.
If moderate-intensity statin therapy is initiated, target a ≥30% LDL-C reduction with a goal of LDL-C <100 mg/dL and non-HDL-C <130 mg/dL.
Consider coronary artery calcium (CAC) test.
Lipid-lowering Therapy
The following groups should receive lipid-lowering therapy regardless of calculated risk:
Established clinical ASCVD.
LDL-C ≥190 mg/dL.
Aged 40–75 with diabetes, chronic kidney disease stage 3 or higher, or HIV on stable combination antiretroviral therapy.
Hypertension
The 2025 AHA/ACC Guideline recommends the following hypertension management (based on 10-year total CVD risk):
BP ≥130/80 mmHg:
Treat if risk estimate ≥7.5%, or if clinical CVD, diabetes, or CKD is present.
If risk estimate is <7.5%, try lifestyle modification for 3–6 months first; start medication if BP remains elevated.
BP ≥140/90 mmHg: Treat all adults regardless of CVD risk estimate.
Risk estimates should be interpreted in the context of:
Patient comorbidities (e.g., diabetes, CKD, obesity).
Risk-enhancing factors (e.g., family history, lipoprotein(a), inflammatory conditions, coronary artery calcium score).
Patient preferences.
Treatment goals.
Based on the 10-year PREVENT-ASCVD estimate for the model that matches the optional predictors entered. Category cutoffs are those reported for the 2026 ACC/AHA dyslipidemia guideline by secondary summaries; confirm against the guideline text before use.
10-year ASCVD risk category: BORDERLINE (3% to <5%) - Female Full Model
Risk thresholds used with PREVENT™️ (e.g., 3%–10%) are evolving and not yet fully validated for management decisions.
Primary Prevention
The 2026 ACC/AHA Guideline uses the following risk categories and recommended primary prevention measures (based on 10-year ASCVD risk):
Health behavior counseling.
Discuss risk-benefit of pharmacotherapy and weigh risk enhancing factors (e.g., family history, lipoprotein(a), inflammatory conditions, coronary artery calcium score) within a framework of shared decision-making.
If moderate-intensity statin therapy is initiated, target a ≥30% LDL-C reduction with a goal of LDL-C <100 mg/dL and non-HDL-C <130 mg/dL.
Consider coronary artery calcium (CAC) test.
Lipid-lowering Therapy
The following groups should receive lipid-lowering therapy regardless of calculated risk:
Established clinical ASCVD.
LDL-C ≥190 mg/dL.
Aged 40–75 with diabetes, chronic kidney disease stage 3 or higher, or HIV on stable combination antiretroviral therapy.
Hypertension
The 2025 AHA/ACC Guideline recommends the following hypertension management (based on 10-year total CVD risk):
BP ≥130/80 mmHg:
Treat if risk estimate ≥7.5%, or if clinical CVD, diabetes, or CKD is present.
If risk estimate is <7.5%, try lifestyle modification for 3–6 months first; start medication if BP remains elevated.
BP ≥140/90 mmHg: Treat all adults regardless of CVD risk estimate.
Risk estimates should be interpreted in the context of:
Patient comorbidities (e.g., diabetes, CKD, obesity).
Risk-enhancing factors (e.g., family history, lipoprotein(a), inflammatory conditions, coronary artery calcium score).
Patient preferences.
Treatment goals.
Based on the 10-year PREVENT-ASCVD estimate for the model that matches the optional predictors entered. Category cutoffs are those reported for the 2026 ACC/AHA dyslipidemia guideline by secondary summaries; confirm against the guideline text before use.
10-year ASCVD risk category: BORDERLINE (3% to <5%) - Female Base + HbA1c Model
Risk thresholds used with PREVENT™️ (e.g., 3%–10%) are evolving and not yet fully validated for management decisions.
Primary Prevention
The 2026 ACC/AHA Guideline uses the following risk categories and recommended primary prevention measures (based on 10-year ASCVD risk):
Health behavior counseling.
Discuss risk-benefit of pharmacotherapy and weigh risk enhancing factors (e.g., family history, lipoprotein(a), inflammatory conditions, coronary artery calcium score) within a framework of shared decision-making.
If moderate-intensity statin therapy is initiated, target a ≥30% LDL-C reduction with a goal of LDL-C <100 mg/dL and non-HDL-C <130 mg/dL.
Consider coronary artery calcium (CAC) test.
Lipid-lowering Therapy
The following groups should receive lipid-lowering therapy regardless of calculated risk:
Established clinical ASCVD.
LDL-C ≥190 mg/dL.
Aged 40–75 with diabetes, chronic kidney disease stage 3 or higher, or HIV on stable combination antiretroviral therapy.
Hypertension
The 2025 AHA/ACC Guideline recommends the following hypertension management (based on 10-year total CVD risk):
BP ≥130/80 mmHg:
Treat if risk estimate ≥7.5%, or if clinical CVD, diabetes, or CKD is present.
If risk estimate is <7.5%, try lifestyle modification for 3–6 months first; start medication if BP remains elevated.
BP ≥140/90 mmHg: Treat all adults regardless of CVD risk estimate.
Risk estimates should be interpreted in the context of:
Patient comorbidities (e.g., diabetes, CKD, obesity).
Risk-enhancing factors (e.g., family history, lipoprotein(a), inflammatory conditions, coronary artery calcium score).
Patient preferences.
Treatment goals.
Based on the 10-year PREVENT-ASCVD estimate for the model that matches the optional predictors entered. Category cutoffs are those reported for the 2026 ACC/AHA dyslipidemia guideline by secondary summaries; confirm against the guideline text before use.
10-year ASCVD risk category: BORDERLINE (3% to <5%) - Male Base + HbA1c Model
Risk thresholds used with PREVENT™️ (e.g., 3%–10%) are evolving and not yet fully validated for management decisions.
Primary Prevention
The 2026 ACC/AHA Guideline uses the following risk categories and recommended primary prevention measures (based on 10-year ASCVD risk):
Health behavior counseling.
Discuss risk-benefit of pharmacotherapy and weigh risk enhancing factors (e.g., family history, lipoprotein(a), inflammatory conditions, coronary artery calcium score) within a framework of shared decision-making.
If moderate-intensity statin therapy is initiated, target a ≥30% LDL-C reduction with a goal of LDL-C <100 mg/dL and non-HDL-C <130 mg/dL.
Consider coronary artery calcium (CAC) test.
Lipid-lowering Therapy
The following groups should receive lipid-lowering therapy regardless of calculated risk:
Established clinical ASCVD.
LDL-C ≥190 mg/dL.
Aged 40–75 with diabetes, chronic kidney disease stage 3 or higher, or HIV on stable combination antiretroviral therapy.
Hypertension
The 2025 AHA/ACC Guideline recommends the following hypertension management (based on 10-year total CVD risk):
BP ≥130/80 mmHg:
Treat if risk estimate ≥7.5%, or if clinical CVD, diabetes, or CKD is present.
If risk estimate is <7.5%, try lifestyle modification for 3–6 months first; start medication if BP remains elevated.
BP ≥140/90 mmHg: Treat all adults regardless of CVD risk estimate.
Risk estimates should be interpreted in the context of:
Patient comorbidities (e.g., diabetes, CKD, obesity).
Risk-enhancing factors (e.g., family history, lipoprotein(a), inflammatory conditions, coronary artery calcium score).
Patient preferences.
Treatment goals.
Based on the 10-year PREVENT-ASCVD estimate for the model that matches the optional predictors entered. Category cutoffs are those reported for the 2026 ACC/AHA dyslipidemia guideline by secondary summaries; confirm against the guideline text before use.
10-year ASCVD risk category: BORDERLINE (3% to <5%) - Male Base + uACR Model
Risk thresholds used with PREVENT™️ (e.g., 3%–10%) are evolving and not yet fully validated for management decisions.
Primary Prevention
The 2026 ACC/AHA Guideline uses the following risk categories and recommended primary prevention measures (based on 10-year ASCVD risk):
Health behavior counseling.
Discuss risk-benefit of pharmacotherapy and weigh risk enhancing factors (e.g., family history, lipoprotein(a), inflammatory conditions, coronary artery calcium score) within a framework of shared decision-making.
If moderate-intensity statin therapy is initiated, target a ≥30% LDL-C reduction with a goal of LDL-C <100 mg/dL and non-HDL-C <130 mg/dL.
Consider coronary artery calcium (CAC) test.
Lipid-lowering Therapy
The following groups should receive lipid-lowering therapy regardless of calculated risk:
Established clinical ASCVD.
LDL-C ≥190 mg/dL.
Aged 40–75 with diabetes, chronic kidney disease stage 3 or higher, or HIV on stable combination antiretroviral therapy.
Hypertension
The 2025 AHA/ACC Guideline recommends the following hypertension management (based on 10-year total CVD risk):
BP ≥130/80 mmHg:
Treat if risk estimate ≥7.5%, or if clinical CVD, diabetes, or CKD is present.
If risk estimate is <7.5%, try lifestyle modification for 3–6 months first; start medication if BP remains elevated.
BP ≥140/90 mmHg: Treat all adults regardless of CVD risk estimate.
Risk estimates should be interpreted in the context of:
Patient comorbidities (e.g., diabetes, CKD, obesity).
Risk-enhancing factors (e.g., family history, lipoprotein(a), inflammatory conditions, coronary artery calcium score).
Patient preferences.
Treatment goals.
Based on the 10-year PREVENT-ASCVD estimate for the model that matches the optional predictors entered. Category cutoffs are those reported for the 2026 ACC/AHA dyslipidemia guideline by secondary summaries; confirm against the guideline text before use.
10-year ASCVD risk category: BORDERLINE (3% to <5%) - Female Base + uACR Model
Risk thresholds used with PREVENT™️ (e.g., 3%–10%) are evolving and not yet fully validated for management decisions.
Primary Prevention
The 2026 ACC/AHA Guideline uses the following risk categories and recommended primary prevention measures (based on 10-year ASCVD risk):
Health behavior counseling.
Discuss risk-benefit of pharmacotherapy and weigh risk enhancing factors (e.g., family history, lipoprotein(a), inflammatory conditions, coronary artery calcium score) within a framework of shared decision-making.
If moderate-intensity statin therapy is initiated, target a ≥30% LDL-C reduction with a goal of LDL-C <100 mg/dL and non-HDL-C <130 mg/dL.
Consider coronary artery calcium (CAC) test.
Lipid-lowering Therapy
The following groups should receive lipid-lowering therapy regardless of calculated risk:
Established clinical ASCVD.
LDL-C ≥190 mg/dL.
Aged 40–75 with diabetes, chronic kidney disease stage 3 or higher, or HIV on stable combination antiretroviral therapy.
Hypertension
The 2025 AHA/ACC Guideline recommends the following hypertension management (based on 10-year total CVD risk):
BP ≥130/80 mmHg:
Treat if risk estimate ≥7.5%, or if clinical CVD, diabetes, or CKD is present.
If risk estimate is <7.5%, try lifestyle modification for 3–6 months first; start medication if BP remains elevated.
BP ≥140/90 mmHg: Treat all adults regardless of CVD risk estimate.
Risk estimates should be interpreted in the context of:
Patient comorbidities (e.g., diabetes, CKD, obesity).
Risk-enhancing factors (e.g., family history, lipoprotein(a), inflammatory conditions, coronary artery calcium score).
Patient preferences.
Treatment goals.
Based on the 10-year PREVENT-ASCVD estimate for the model that matches the optional predictors entered. Category cutoffs are those reported for the 2026 ACC/AHA dyslipidemia guideline by secondary summaries; confirm against the guideline text before use.
10-year ASCVD risk category: BORDERLINE (3% to <5%) - Female Base + SDI Model
Risk thresholds used with PREVENT™️ (e.g., 3%–10%) are evolving and not yet fully validated for management decisions.
Primary Prevention
The 2026 ACC/AHA Guideline uses the following risk categories and recommended primary prevention measures (based on 10-year ASCVD risk):
Health behavior counseling.
Discuss risk-benefit of pharmacotherapy and weigh risk enhancing factors (e.g., family history, lipoprotein(a), inflammatory conditions, coronary artery calcium score) within a framework of shared decision-making.
If moderate-intensity statin therapy is initiated, target a ≥30% LDL-C reduction with a goal of LDL-C <100 mg/dL and non-HDL-C <130 mg/dL.
Consider coronary artery calcium (CAC) test.
Lipid-lowering Therapy
The following groups should receive lipid-lowering therapy regardless of calculated risk:
Established clinical ASCVD.
LDL-C ≥190 mg/dL.
Aged 40–75 with diabetes, chronic kidney disease stage 3 or higher, or HIV on stable combination antiretroviral therapy.
Hypertension
The 2025 AHA/ACC Guideline recommends the following hypertension management (based on 10-year total CVD risk):
BP ≥130/80 mmHg:
Treat if risk estimate ≥7.5%, or if clinical CVD, diabetes, or CKD is present.
If risk estimate is <7.5%, try lifestyle modification for 3–6 months first; start medication if BP remains elevated.
BP ≥140/90 mmHg: Treat all adults regardless of CVD risk estimate.
Risk estimates should be interpreted in the context of:
Patient comorbidities (e.g., diabetes, CKD, obesity).
Risk-enhancing factors (e.g., family history, lipoprotein(a), inflammatory conditions, coronary artery calcium score).
Patient preferences.
Treatment goals.
Based on the 10-year PREVENT-ASCVD estimate for the model that matches the optional predictors entered. Category cutoffs are those reported for the 2026 ACC/AHA dyslipidemia guideline by secondary summaries; confirm against the guideline text before use.
10-year ASCVD risk category: BORDERLINE (3% to <5%) - Male Base + SDI Model
Risk thresholds used with PREVENT™️ (e.g., 3%–10%) are evolving and not yet fully validated for management decisions.
Primary Prevention
The 2026 ACC/AHA Guideline uses the following risk categories and recommended primary prevention measures (based on 10-year ASCVD risk):
Health behavior counseling.
Discuss risk-benefit of pharmacotherapy and weigh risk enhancing factors (e.g., family history, lipoprotein(a), inflammatory conditions, coronary artery calcium score) within a framework of shared decision-making.
If moderate-intensity statin therapy is initiated, target a ≥30% LDL-C reduction with a goal of LDL-C <100 mg/dL and non-HDL-C <130 mg/dL.
Consider coronary artery calcium (CAC) test.
Lipid-lowering Therapy
The following groups should receive lipid-lowering therapy regardless of calculated risk:
Established clinical ASCVD.
LDL-C ≥190 mg/dL.
Aged 40–75 with diabetes, chronic kidney disease stage 3 or higher, or HIV on stable combination antiretroviral therapy.
Hypertension
The 2025 AHA/ACC Guideline recommends the following hypertension management (based on 10-year total CVD risk):
BP ≥130/80 mmHg:
Treat if risk estimate ≥7.5%, or if clinical CVD, diabetes, or CKD is present.
If risk estimate is <7.5%, try lifestyle modification for 3–6 months first; start medication if BP remains elevated.
BP ≥140/90 mmHg: Treat all adults regardless of CVD risk estimate.
Risk estimates should be interpreted in the context of:
Patient comorbidities (e.g., diabetes, CKD, obesity).
Risk-enhancing factors (e.g., family history, lipoprotein(a), inflammatory conditions, coronary artery calcium score).
Patient preferences.
Treatment goals.
Based on the 10-year PREVENT-ASCVD estimate for the model that matches the optional predictors entered. Category cutoffs are those reported for the 2026 ACC/AHA dyslipidemia guideline by secondary summaries; confirm against the guideline text before use.
10-year ASCVD risk category: INTERMEDIATE (5% to <10%) - Male Base Model
Risk thresholds used with PREVENT™️ (e.g., 3%–10%) are evolving and not yet fully validated for management decisions.
Primary Prevention
The 2026 ACC/AHA Guideline uses the following risk categories and recommended primary prevention measures (based on 10-year ASCVD risk):
Health behavior counseling.
Discuss risk-benefit of pharmacotherapy and weigh risk enhancing factors (e.g., family history, lipoprotein(a), inflammatory conditions, coronary artery calcium score) within a framework of shared decision-making.
Start moderate- to high-intensity statin therapy, targeting a ≥30% LDL-C reduction with a goal of LDL-C <100 mg/dL and non-HDL-C <130 mg/dL.
Consider coronary artery calcium (CAC) test.
Lipid-lowering Therapy
The following groups should receive lipid-lowering therapy regardless of calculated risk:
Established clinical ASCVD.
LDL-C ≥190 mg/dL.
Aged 40–75 with diabetes, chronic kidney disease stage 3 or higher, or HIV on stable combination antiretroviral therapy.
Hypertension
The 2025 AHA/ACC Guideline recommends the following hypertension management (based on 10-year total CVD risk):
BP ≥130/80 mmHg:
Treat if risk estimate ≥7.5%, or if clinical CVD, diabetes, or CKD is present.
If risk estimate is <7.5%, try lifestyle modification for 3–6 months first; start medication if BP remains elevated.
BP ≥140/90 mmHg: Treat all adults regardless of CVD risk estimate.
Risk estimates should be interpreted in the context of:
Patient comorbidities (e.g., diabetes, CKD, obesity).
Risk-enhancing factors (e.g., family history, lipoprotein(a), inflammatory conditions, coronary artery calcium score).
Patient preferences.
Treatment goals.
Based on the 10-year PREVENT-ASCVD estimate for the model that matches the optional predictors entered. Category cutoffs are those reported for the 2026 ACC/AHA dyslipidemia guideline by secondary summaries; confirm against the guideline text before use.
10-year ASCVD risk category: INTERMEDIATE (5% to <10%) - Male Full Model
Risk thresholds used with PREVENT™️ (e.g., 3%–10%) are evolving and not yet fully validated for management decisions.
Primary Prevention
The 2026 ACC/AHA Guideline uses the following risk categories and recommended primary prevention measures (based on 10-year ASCVD risk):
Health behavior counseling.
Discuss risk-benefit of pharmacotherapy and weigh risk enhancing factors (e.g., family history, lipoprotein(a), inflammatory conditions, coronary artery calcium score) within a framework of shared decision-making.
Start moderate- to high-intensity statin therapy, targeting a ≥30% LDL-C reduction with a goal of LDL-C <100 mg/dL and non-HDL-C <130 mg/dL.
Consider coronary artery calcium (CAC) test.
Lipid-lowering Therapy
The following groups should receive lipid-lowering therapy regardless of calculated risk:
Established clinical ASCVD.
LDL-C ≥190 mg/dL.
Aged 40–75 with diabetes, chronic kidney disease stage 3 or higher, or HIV on stable combination antiretroviral therapy.
Hypertension
The 2025 AHA/ACC Guideline recommends the following hypertension management (based on 10-year total CVD risk):
BP ≥130/80 mmHg:
Treat if risk estimate ≥7.5%, or if clinical CVD, diabetes, or CKD is present.
If risk estimate is <7.5%, try lifestyle modification for 3–6 months first; start medication if BP remains elevated.
BP ≥140/90 mmHg: Treat all adults regardless of CVD risk estimate.
Risk estimates should be interpreted in the context of:
Patient comorbidities (e.g., diabetes, CKD, obesity).
Risk-enhancing factors (e.g., family history, lipoprotein(a), inflammatory conditions, coronary artery calcium score).
Patient preferences.
Treatment goals.
Based on the 10-year PREVENT-ASCVD estimate for the model that matches the optional predictors entered. Category cutoffs are those reported for the 2026 ACC/AHA dyslipidemia guideline by secondary summaries; confirm against the guideline text before use.
10-year ASCVD risk category: INTERMEDIATE (5% to <10%) - Female Full Model
Risk thresholds used with PREVENT™️ (e.g., 3%–10%) are evolving and not yet fully validated for management decisions.
Primary Prevention
The 2026 ACC/AHA Guideline uses the following risk categories and recommended primary prevention measures (based on 10-year ASCVD risk):
Health behavior counseling.
Discuss risk-benefit of pharmacotherapy and weigh risk enhancing factors (e.g., family history, lipoprotein(a), inflammatory conditions, coronary artery calcium score) within a framework of shared decision-making.
Start moderate- to high-intensity statin therapy, targeting a ≥30% LDL-C reduction with a goal of LDL-C <100 mg/dL and non-HDL-C <130 mg/dL.
Consider coronary artery calcium (CAC) test.
Lipid-lowering Therapy
The following groups should receive lipid-lowering therapy regardless of calculated risk:
Established clinical ASCVD.
LDL-C ≥190 mg/dL.
Aged 40–75 with diabetes, chronic kidney disease stage 3 or higher, or HIV on stable combination antiretroviral therapy.
Hypertension
The 2025 AHA/ACC Guideline recommends the following hypertension management (based on 10-year total CVD risk):
BP ≥130/80 mmHg:
Treat if risk estimate ≥7.5%, or if clinical CVD, diabetes, or CKD is present.
If risk estimate is <7.5%, try lifestyle modification for 3–6 months first; start medication if BP remains elevated.
BP ≥140/90 mmHg: Treat all adults regardless of CVD risk estimate.
Risk estimates should be interpreted in the context of:
Patient comorbidities (e.g., diabetes, CKD, obesity).
Risk-enhancing factors (e.g., family history, lipoprotein(a), inflammatory conditions, coronary artery calcium score).
Patient preferences.
Treatment goals.
Based on the 10-year PREVENT-ASCVD estimate for the model that matches the optional predictors entered. Category cutoffs are those reported for the 2026 ACC/AHA dyslipidemia guideline by secondary summaries; confirm against the guideline text before use.
10-year ASCVD risk category: INTERMEDIATE (5% to <10%) - Female Base + HbA1c Model
Risk thresholds used with PREVENT™️ (e.g., 3%–10%) are evolving and not yet fully validated for management decisions.
Primary Prevention
The 2026 ACC/AHA Guideline uses the following risk categories and recommended primary prevention measures (based on 10-year ASCVD risk):
Health behavior counseling.
Discuss risk-benefit of pharmacotherapy and weigh risk enhancing factors (e.g., family history, lipoprotein(a), inflammatory conditions, coronary artery calcium score) within a framework of shared decision-making.
Start moderate- to high-intensity statin therapy, targeting a ≥30% LDL-C reduction with a goal of LDL-C <100 mg/dL and non-HDL-C <130 mg/dL.
Consider coronary artery calcium (CAC) test.
Lipid-lowering Therapy
The following groups should receive lipid-lowering therapy regardless of calculated risk:
Established clinical ASCVD.
LDL-C ≥190 mg/dL.
Aged 40–75 with diabetes, chronic kidney disease stage 3 or higher, or HIV on stable combination antiretroviral therapy.
Hypertension
The 2025 AHA/ACC Guideline recommends the following hypertension management (based on 10-year total CVD risk):
BP ≥130/80 mmHg:
Treat if risk estimate ≥7.5%, or if clinical CVD, diabetes, or CKD is present.
If risk estimate is <7.5%, try lifestyle modification for 3–6 months first; start medication if BP remains elevated.
BP ≥140/90 mmHg: Treat all adults regardless of CVD risk estimate.
Risk estimates should be interpreted in the context of:
Patient comorbidities (e.g., diabetes, CKD, obesity).
Risk-enhancing factors (e.g., family history, lipoprotein(a), inflammatory conditions, coronary artery calcium score).
Patient preferences.
Treatment goals.
Based on the 10-year PREVENT-ASCVD estimate for the model that matches the optional predictors entered. Category cutoffs are those reported for the 2026 ACC/AHA dyslipidemia guideline by secondary summaries; confirm against the guideline text before use.
10-year ASCVD risk category: INTERMEDIATE (5% to <10%) - Male Base + HbA1c Model
Risk thresholds used with PREVENT™️ (e.g., 3%–10%) are evolving and not yet fully validated for management decisions.
Primary Prevention
The 2026 ACC/AHA Guideline uses the following risk categories and recommended primary prevention measures (based on 10-year ASCVD risk):
Health behavior counseling.
Discuss risk-benefit of pharmacotherapy and weigh risk enhancing factors (e.g., family history, lipoprotein(a), inflammatory conditions, coronary artery calcium score) within a framework of shared decision-making.
Start moderate- to high-intensity statin therapy, targeting a ≥30% LDL-C reduction with a goal of LDL-C <100 mg/dL and non-HDL-C <130 mg/dL.
Consider coronary artery calcium (CAC) test.
Lipid-lowering Therapy
The following groups should receive lipid-lowering therapy regardless of calculated risk:
Established clinical ASCVD.
LDL-C ≥190 mg/dL.
Aged 40–75 with diabetes, chronic kidney disease stage 3 or higher, or HIV on stable combination antiretroviral therapy.
Hypertension
The 2025 AHA/ACC Guideline recommends the following hypertension management (based on 10-year total CVD risk):
BP ≥130/80 mmHg:
Treat if risk estimate ≥7.5%, or if clinical CVD, diabetes, or CKD is present.
If risk estimate is <7.5%, try lifestyle modification for 3–6 months first; start medication if BP remains elevated.
BP ≥140/90 mmHg: Treat all adults regardless of CVD risk estimate.
Risk estimates should be interpreted in the context of:
Patient comorbidities (e.g., diabetes, CKD, obesity).
Risk-enhancing factors (e.g., family history, lipoprotein(a), inflammatory conditions, coronary artery calcium score).
Patient preferences.
Treatment goals.
Based on the 10-year PREVENT-ASCVD estimate for the model that matches the optional predictors entered. Category cutoffs are those reported for the 2026 ACC/AHA dyslipidemia guideline by secondary summaries; confirm against the guideline text before use.
10-year ASCVD risk category: INTERMEDIATE (5% to <10%) - Male Base + uACR Model
Risk thresholds used with PREVENT™️ (e.g., 3%–10%) are evolving and not yet fully validated for management decisions.
Primary Prevention
The 2026 ACC/AHA Guideline uses the following risk categories and recommended primary prevention measures (based on 10-year ASCVD risk):
Health behavior counseling.
Discuss risk-benefit of pharmacotherapy and weigh risk enhancing factors (e.g., family history, lipoprotein(a), inflammatory conditions, coronary artery calcium score) within a framework of shared decision-making.
Start moderate- to high-intensity statin therapy, targeting a ≥30% LDL-C reduction with a goal of LDL-C <100 mg/dL and non-HDL-C <130 mg/dL.
Consider coronary artery calcium (CAC) test.
Lipid-lowering Therapy
The following groups should receive lipid-lowering therapy regardless of calculated risk:
Established clinical ASCVD.
LDL-C ≥190 mg/dL.
Aged 40–75 with diabetes, chronic kidney disease stage 3 or higher, or HIV on stable combination antiretroviral therapy.
Hypertension
The 2025 AHA/ACC Guideline recommends the following hypertension management (based on 10-year total CVD risk):
BP ≥130/80 mmHg:
Treat if risk estimate ≥7.5%, or if clinical CVD, diabetes, or CKD is present.
If risk estimate is <7.5%, try lifestyle modification for 3–6 months first; start medication if BP remains elevated.
BP ≥140/90 mmHg: Treat all adults regardless of CVD risk estimate.
Risk estimates should be interpreted in the context of:
Patient comorbidities (e.g., diabetes, CKD, obesity).
Risk-enhancing factors (e.g., family history, lipoprotein(a), inflammatory conditions, coronary artery calcium score).
Patient preferences.
Treatment goals.
Based on the 10-year PREVENT-ASCVD estimate for the model that matches the optional predictors entered. Category cutoffs are those reported for the 2026 ACC/AHA dyslipidemia guideline by secondary summaries; confirm against the guideline text before use.
10-year ASCVD risk category: INTERMEDIATE (5% to <10%) - Female Base + SDI Model
Risk thresholds used with PREVENT™️ (e.g., 3%–10%) are evolving and not yet fully validated for management decisions.
Primary Prevention
The 2026 ACC/AHA Guideline uses the following risk categories and recommended primary prevention measures (based on 10-year ASCVD risk):
Health behavior counseling.
Discuss risk-benefit of pharmacotherapy and weigh risk enhancing factors (e.g., family history, lipoprotein(a), inflammatory conditions, coronary artery calcium score) within a framework of shared decision-making.
Start moderate- to high-intensity statin therapy, targeting a ≥30% LDL-C reduction with a goal of LDL-C <100 mg/dL and non-HDL-C <130 mg/dL.
Consider coronary artery calcium (CAC) test.
Lipid-lowering Therapy
The following groups should receive lipid-lowering therapy regardless of calculated risk:
Established clinical ASCVD.
LDL-C ≥190 mg/dL.
Aged 40–75 with diabetes, chronic kidney disease stage 3 or higher, or HIV on stable combination antiretroviral therapy.
Hypertension
The 2025 AHA/ACC Guideline recommends the following hypertension management (based on 10-year total CVD risk):
BP ≥130/80 mmHg:
Treat if risk estimate ≥7.5%, or if clinical CVD, diabetes, or CKD is present.
If risk estimate is <7.5%, try lifestyle modification for 3–6 months first; start medication if BP remains elevated.
BP ≥140/90 mmHg: Treat all adults regardless of CVD risk estimate.
Risk estimates should be interpreted in the context of:
Patient comorbidities (e.g., diabetes, CKD, obesity).
Risk-enhancing factors (e.g., family history, lipoprotein(a), inflammatory conditions, coronary artery calcium score).
Patient preferences.
Treatment goals.
Based on the 10-year PREVENT-ASCVD estimate for the model that matches the optional predictors entered. Category cutoffs are those reported for the 2026 ACC/AHA dyslipidemia guideline by secondary summaries; confirm against the guideline text before use.
10-year ASCVD risk category: INTERMEDIATE (5% to <10%) - Male Base + SDI Model
Risk thresholds used with PREVENT™️ (e.g., 3%–10%) are evolving and not yet fully validated for management decisions.
Primary Prevention
The 2026 ACC/AHA Guideline uses the following risk categories and recommended primary prevention measures (based on 10-year ASCVD risk):
Health behavior counseling.
Discuss risk-benefit of pharmacotherapy and weigh risk enhancing factors (e.g., family history, lipoprotein(a), inflammatory conditions, coronary artery calcium score) within a framework of shared decision-making.
Start moderate- to high-intensity statin therapy, targeting a ≥30% LDL-C reduction with a goal of LDL-C <100 mg/dL and non-HDL-C <130 mg/dL.
Consider coronary artery calcium (CAC) test.
Lipid-lowering Therapy
The following groups should receive lipid-lowering therapy regardless of calculated risk:
Established clinical ASCVD.
LDL-C ≥190 mg/dL.
Aged 40–75 with diabetes, chronic kidney disease stage 3 or higher, or HIV on stable combination antiretroviral therapy.
Hypertension
The 2025 AHA/ACC Guideline recommends the following hypertension management (based on 10-year total CVD risk):
BP ≥130/80 mmHg:
Treat if risk estimate ≥7.5%, or if clinical CVD, diabetes, or CKD is present.
If risk estimate is <7.5%, try lifestyle modification for 3–6 months first; start medication if BP remains elevated.
BP ≥140/90 mmHg: Treat all adults regardless of CVD risk estimate.
Risk estimates should be interpreted in the context of:
Patient comorbidities (e.g., diabetes, CKD, obesity).
Risk-enhancing factors (e.g., family history, lipoprotein(a), inflammatory conditions, coronary artery calcium score).
Patient preferences.
Treatment goals.
Based on the 10-year PREVENT-ASCVD estimate for the model that matches the optional predictors entered. Category cutoffs are those reported for the 2026 ACC/AHA dyslipidemia guideline by secondary summaries; confirm against the guideline text before use.
10-year ASCVD risk category: High (≥10%) - Male Full Model
Risk thresholds used with PREVENT™️ (e.g., 3%–10%) are evolving and not yet fully validated for management decisions.
Primary Prevention
The 2026 ACC/AHA Guideline uses the following risk categories and recommended primary prevention measures (based on 10-year ASCVD risk):
Health behavior counseling.
Discuss risk-benefit of pharmacotherapy and weigh risk enhancing factors (e.g., family history, lipoprotein(a), inflammatory conditions, coronary artery calcium score) within a framework of shared decision-making.
Start high-intensity statin therapy, targeting a ≥50% LDL-C reduction with a goal of LDL-C <70 mg/dL and non-HDL-C <100 mg/dL.
If goals are not achieved on maximally tolerated statin therapy, additional therapies (e.g., ezetimibe, PCSK9 inhibitors, bempedoic acid) may be necessary.
Consider coronary artery calcium (CAC) test.
Lipid-lowering Therapy
The following groups should receive lipid-lowering therapy regardless of calculated risk:
Established clinical ASCVD.
LDL-C ≥190 mg/dL.
Aged 40–75 with diabetes, chronic kidney disease stage 3 or higher, or HIV on stable combination antiretroviral therapy.
Hypertension
The 2025 AHA/ACC Guideline recommends the following hypertension management (based on 10-year total CVD risk):
BP ≥130/80 mmHg:
Treat if risk estimate ≥7.5%, or if clinical CVD, diabetes, or CKD is present.
If risk estimate is <7.5%, try lifestyle modification for 3–6 months first; start medication if BP remains elevated.
BP ≥140/90 mmHg: Treat all adults regardless of CVD risk estimate.
Risk estimates should be interpreted in the context of:
Patient comorbidities (e.g., diabetes, CKD, obesity).
Risk-enhancing factors (e.g., family history, lipoprotein(a), inflammatory conditions, coronary artery calcium score).
Patient preferences.
Treatment goals.
Based on the 10-year PREVENT-ASCVD estimate for the model that matches the optional predictors entered. Category cutoffs are those reported for the 2026 ACC/AHA dyslipidemia guideline by secondary summaries; confirm against the guideline text before use.
10-year ASCVD risk category: High (≥10%) - Female Full Model
Risk thresholds used with PREVENT™️ (e.g., 3%–10%) are evolving and not yet fully validated for management decisions.
Primary Prevention
The 2026 ACC/AHA Guideline uses the following risk categories and recommended primary prevention measures (based on 10-year ASCVD risk):
Health behavior counseling.
Discuss risk-benefit of pharmacotherapy and weigh risk enhancing factors (e.g., family history, lipoprotein(a), inflammatory conditions, coronary artery calcium score) within a framework of shared decision-making.
Start high-intensity statin therapy, targeting a ≥50% LDL-C reduction with a goal of LDL-C <70 mg/dL and non-HDL-C <100 mg/dL.
If goals are not achieved on maximally tolerated statin therapy, additional therapies (e.g., ezetimibe, PCSK9 inhibitors, bempedoic acid) may be necessary.
Consider coronary artery calcium (CAC) test.
Lipid-lowering Therapy
The following groups should receive lipid-lowering therapy regardless of calculated risk:
Established clinical ASCVD.
LDL-C ≥190 mg/dL.
Aged 40–75 with diabetes, chronic kidney disease stage 3 or higher, or HIV on stable combination antiretroviral therapy.
Hypertension
The 2025 AHA/ACC Guideline recommends the following hypertension management (based on 10-year total CVD risk):
BP ≥130/80 mmHg:
Treat if risk estimate ≥7.5%, or if clinical CVD, diabetes, or CKD is present.
If risk estimate is <7.5%, try lifestyle modification for 3–6 months first; start medication if BP remains elevated.
BP ≥140/90 mmHg: Treat all adults regardless of CVD risk estimate.
Risk estimates should be interpreted in the context of:
Patient comorbidities (e.g., diabetes, CKD, obesity).
Risk-enhancing factors (e.g., family history, lipoprotein(a), inflammatory conditions, coronary artery calcium score).
Patient preferences.
Treatment goals.
Based on the 10-year PREVENT-ASCVD estimate for the model that matches the optional predictors entered. Category cutoffs are those reported for the 2026 ACC/AHA dyslipidemia guideline by secondary summaries; confirm against the guideline text before use.
10-year ASCVD risk category: High (≥10%) - Female Base + HbA1c Model
Risk thresholds used with PREVENT™️ (e.g., 3%–10%) are evolving and not yet fully validated for management decisions.
Primary Prevention
The 2026 ACC/AHA Guideline uses the following risk categories and recommended primary prevention measures (based on 10-year ASCVD risk):
Health behavior counseling.
Discuss risk-benefit of pharmacotherapy and weigh risk enhancing factors (e.g., family history, lipoprotein(a), inflammatory conditions, coronary artery calcium score) within a framework of shared decision-making.
Start high-intensity statin therapy, targeting a ≥50% LDL-C reduction with a goal of LDL-C <70 mg/dL and non-HDL-C <100 mg/dL.
If goals are not achieved on maximally tolerated statin therapy, additional therapies (e.g., ezetimibe, PCSK9 inhibitors, bempedoic acid) may be necessary.
Consider coronary artery calcium (CAC) test.
Lipid-lowering Therapy
The following groups should receive lipid-lowering therapy regardless of calculated risk:
Established clinical ASCVD.
LDL-C ≥190 mg/dL.
Aged 40–75 with diabetes, chronic kidney disease stage 3 or higher, or HIV on stable combination antiretroviral therapy.
Hypertension
The 2025 AHA/ACC Guideline recommends the following hypertension management (based on 10-year total CVD risk):
BP ≥130/80 mmHg:
Treat if risk estimate ≥7.5%, or if clinical CVD, diabetes, or CKD is present.
If risk estimate is <7.5%, try lifestyle modification for 3–6 months first; start medication if BP remains elevated.
BP ≥140/90 mmHg: Treat all adults regardless of CVD risk estimate.
Risk estimates should be interpreted in the context of:
Patient comorbidities (e.g., diabetes, CKD, obesity).
Risk-enhancing factors (e.g., family history, lipoprotein(a), inflammatory conditions, coronary artery calcium score).
Patient preferences.
Treatment goals.
Based on the 10-year PREVENT-ASCVD estimate for the model that matches the optional predictors entered. Category cutoffs are those reported for the 2026 ACC/AHA dyslipidemia guideline by secondary summaries; confirm against the guideline text before use.
10-year ASCVD risk category: High (≥10%) - Male Base + HbA1c Model
Risk thresholds used with PREVENT™️ (e.g., 3%–10%) are evolving and not yet fully validated for management decisions.
Primary Prevention
The 2026 ACC/AHA Guideline uses the following risk categories and recommended primary prevention measures (based on 10-year ASCVD risk):
Health behavior counseling.
Discuss risk-benefit of pharmacotherapy and weigh risk enhancing factors (e.g., family history, lipoprotein(a), inflammatory conditions, coronary artery calcium score) within a framework of shared decision-making.
Start high-intensity statin therapy, targeting a ≥50% LDL-C reduction with a goal of LDL-C <70 mg/dL and non-HDL-C <100 mg/dL.
If goals are not achieved on maximally tolerated statin therapy, additional therapies (e.g., ezetimibe, PCSK9 inhibitors, bempedoic acid) may be necessary.
Consider coronary artery calcium (CAC) test.
Lipid-lowering Therapy
The following groups should receive lipid-lowering therapy regardless of calculated risk:
Established clinical ASCVD.
LDL-C ≥190 mg/dL.
Aged 40–75 with diabetes, chronic kidney disease stage 3 or higher, or HIV on stable combination antiretroviral therapy.
Hypertension
The 2025 AHA/ACC Guideline recommends the following hypertension management (based on 10-year total CVD risk):
BP ≥130/80 mmHg:
Treat if risk estimate ≥7.5%, or if clinical CVD, diabetes, or CKD is present.
If risk estimate is <7.5%, try lifestyle modification for 3–6 months first; start medication if BP remains elevated.
BP ≥140/90 mmHg: Treat all adults regardless of CVD risk estimate.
Risk estimates should be interpreted in the context of:
Patient comorbidities (e.g., diabetes, CKD, obesity).
Risk-enhancing factors (e.g., family history, lipoprotein(a), inflammatory conditions, coronary artery calcium score).
Patient preferences.
Treatment goals.
Based on the 10-year PREVENT-ASCVD estimate for the model that matches the optional predictors entered. Category cutoffs are those reported for the 2026 ACC/AHA dyslipidemia guideline by secondary summaries; confirm against the guideline text before use.
10-year ASCVD risk category: High (≥10%) - Male Base + uACR Model
Risk thresholds used with PREVENT™️ (e.g., 3%–10%) are evolving and not yet fully validated for management decisions.
Primary Prevention
The 2026 ACC/AHA Guideline uses the following risk categories and recommended primary prevention measures (based on 10-year ASCVD risk):
Health behavior counseling.
Discuss risk-benefit of pharmacotherapy and weigh risk enhancing factors (e.g., family history, lipoprotein(a), inflammatory conditions, coronary artery calcium score) within a framework of shared decision-making.
Start high-intensity statin therapy, targeting a ≥50% LDL-C reduction with a goal of LDL-C <70 mg/dL and non-HDL-C <100 mg/dL.
If goals are not achieved on maximally tolerated statin therapy, additional therapies (e.g., ezetimibe, PCSK9 inhibitors, bempedoic acid) may be necessary.
Consider coronary artery calcium (CAC) test.
Lipid-lowering Therapy
The following groups should receive lipid-lowering therapy regardless of calculated risk:
Established clinical ASCVD.
LDL-C ≥190 mg/dL.
Aged 40–75 with diabetes, chronic kidney disease stage 3 or higher, or HIV on stable combination antiretroviral therapy.
Hypertension
The 2025 AHA/ACC Guideline recommends the following hypertension management (based on 10-year total CVD risk):
BP ≥130/80 mmHg:
Treat if risk estimate ≥7.5%, or if clinical CVD, diabetes, or CKD is present.
If risk estimate is <7.5%, try lifestyle modification for 3–6 months first; start medication if BP remains elevated.
BP ≥140/90 mmHg: Treat all adults regardless of CVD risk estimate.
Risk estimates should be interpreted in the context of:
Patient comorbidities (e.g., diabetes, CKD, obesity).
Risk-enhancing factors (e.g., family history, lipoprotein(a), inflammatory conditions, coronary artery calcium score).
Patient preferences.
Treatment goals.
Based on the 10-year PREVENT-ASCVD estimate for the model that matches the optional predictors entered. Category cutoffs are those reported for the 2026 ACC/AHA dyslipidemia guideline by secondary summaries; confirm against the guideline text before use.
10-year ASCVD risk category: High (≥10%) - Female Base + uACR Model
Risk thresholds used with PREVENT™️ (e.g., 3%–10%) are evolving and not yet fully validated for management decisions.
Primary Prevention
The 2026 ACC/AHA Guideline uses the following risk categories and recommended primary prevention measures (based on 10-year ASCVD risk):
Health behavior counseling.
Discuss risk-benefit of pharmacotherapy and weigh risk enhancing factors (e.g., family history, lipoprotein(a), inflammatory conditions, coronary artery calcium score) within a framework of shared decision-making.
Start high-intensity statin therapy, targeting a ≥50% LDL-C reduction with a goal of LDL-C <70 mg/dL and non-HDL-C <100 mg/dL.
If goals are not achieved on maximally tolerated statin therapy, additional therapies (e.g., ezetimibe, PCSK9 inhibitors, bempedoic acid) may be necessary.
Consider coronary artery calcium (CAC) test.
Lipid-lowering Therapy
The following groups should receive lipid-lowering therapy regardless of calculated risk:
Established clinical ASCVD.
LDL-C ≥190 mg/dL.
Aged 40–75 with diabetes, chronic kidney disease stage 3 or higher, or HIV on stable combination antiretroviral therapy.
Hypertension
The 2025 AHA/ACC Guideline recommends the following hypertension management (based on 10-year total CVD risk):
BP ≥130/80 mmHg:
Treat if risk estimate ≥7.5%, or if clinical CVD, diabetes, or CKD is present.
If risk estimate is <7.5%, try lifestyle modification for 3–6 months first; start medication if BP remains elevated.
BP ≥140/90 mmHg: Treat all adults regardless of CVD risk estimate.
Risk estimates should be interpreted in the context of:
Patient comorbidities (e.g., diabetes, CKD, obesity).
Risk-enhancing factors (e.g., family history, lipoprotein(a), inflammatory conditions, coronary artery calcium score).
Patient preferences.
Treatment goals.
Based on the 10-year PREVENT-ASCVD estimate for the model that matches the optional predictors entered. Category cutoffs are those reported for the 2026 ACC/AHA dyslipidemia guideline by secondary summaries; confirm against the guideline text before use.
10-year ASCVD risk category: High (≥10%) - Female Base + SDI Model
Risk thresholds used with PREVENT™️ (e.g., 3%–10%) are evolving and not yet fully validated for management decisions.
Primary Prevention
The 2026 ACC/AHA Guideline uses the following risk categories and recommended primary prevention measures (based on 10-year ASCVD risk):
Health behavior counseling.
Discuss risk-benefit of pharmacotherapy and weigh risk enhancing factors (e.g., family history, lipoprotein(a), inflammatory conditions, coronary artery calcium score) within a framework of shared decision-making.
Start high-intensity statin therapy, targeting a ≥50% LDL-C reduction with a goal of LDL-C <70 mg/dL and non-HDL-C <100 mg/dL.
If goals are not achieved on maximally tolerated statin therapy, additional therapies (e.g., ezetimibe, PCSK9 inhibitors, bempedoic acid) may be necessary.
Consider coronary artery calcium (CAC) test.
Lipid-lowering Therapy
The following groups should receive lipid-lowering therapy regardless of calculated risk:
Established clinical ASCVD.
LDL-C ≥190 mg/dL.
Aged 40–75 with diabetes, chronic kidney disease stage 3 or higher, or HIV on stable combination antiretroviral therapy.
Hypertension
The 2025 AHA/ACC Guideline recommends the following hypertension management (based on 10-year total CVD risk):
BP ≥130/80 mmHg:
Treat if risk estimate ≥7.5%, or if clinical CVD, diabetes, or CKD is present.
If risk estimate is <7.5%, try lifestyle modification for 3–6 months first; start medication if BP remains elevated.
BP ≥140/90 mmHg: Treat all adults regardless of CVD risk estimate.
Risk estimates should be interpreted in the context of:
Patient comorbidities (e.g., diabetes, CKD, obesity).
Risk-enhancing factors (e.g., family history, lipoprotein(a), inflammatory conditions, coronary artery calcium score).
Patient preferences.
Treatment goals.
Based on the 10-year PREVENT-ASCVD estimate for the model that matches the optional predictors entered. Category cutoffs are those reported for the 2026 ACC/AHA dyslipidemia guideline by secondary summaries; confirm against the guideline text before use.
10-year ASCVD risk category: High (≥10%) - Male Base + SDI Model
Risk thresholds used with PREVENT™️ (e.g., 3%–10%) are evolving and not yet fully validated for management decisions.
Primary Prevention
The 2026 ACC/AHA Guideline uses the following risk categories and recommended primary prevention measures (based on 10-year ASCVD risk):
Health behavior counseling.
Discuss risk-benefit of pharmacotherapy and weigh risk enhancing factors (e.g., family history, lipoprotein(a), inflammatory conditions, coronary artery calcium score) within a framework of shared decision-making.
Start high-intensity statin therapy, targeting a ≥50% LDL-C reduction with a goal of LDL-C <70 mg/dL and non-HDL-C <100 mg/dL.
If goals are not achieved on maximally tolerated statin therapy, additional therapies (e.g., ezetimibe, PCSK9 inhibitors, bempedoic acid) may be necessary.
Consider coronary artery calcium (CAC) test.
Lipid-lowering Therapy
The following groups should receive lipid-lowering therapy regardless of calculated risk:
Established clinical ASCVD.
LDL-C ≥190 mg/dL.
Aged 40–75 with diabetes, chronic kidney disease stage 3 or higher, or HIV on stable combination antiretroviral therapy.
Hypertension
The 2025 AHA/ACC Guideline recommends the following hypertension management (based on 10-year total CVD risk):
BP ≥130/80 mmHg:
Treat if risk estimate ≥7.5%, or if clinical CVD, diabetes, or CKD is present.
If risk estimate is <7.5%, try lifestyle modification for 3–6 months first; start medication if BP remains elevated.
BP ≥140/90 mmHg: Treat all adults regardless of CVD risk estimate.
Risk estimates should be interpreted in the context of:
Patient comorbidities (e.g., diabetes, CKD, obesity).
Risk-enhancing factors (e.g., family history, lipoprotein(a), inflammatory conditions, coronary artery calcium score).
Patient preferences.
Treatment goals.
Based on the 10-year PREVENT-ASCVD estimate for the model that matches the optional predictors entered. Category cutoffs are those reported for the 2026 ACC/AHA dyslipidemia guideline by secondary summaries; confirm against the guideline text before use.
10-year ASCVD risk category: High (≥10%) - Male Base Model
Risk thresholds used with PREVENT™️ (e.g., 3%–10%) are evolving and not yet fully validated for management decisions.
Primary Prevention
The 2026 ACC/AHA Guideline uses the following risk categories and recommended primary prevention measures (based on 10-year ASCVD risk):
Health behavior counseling.
Discuss risk-benefit of pharmacotherapy and weigh risk enhancing factors (e.g., family history, lipoprotein(a), inflammatory conditions, coronary artery calcium score) within a framework of shared decision-making.
Start high-intensity statin therapy, targeting a ≥50% LDL-C reduction with a goal of LDL-C <70 mg/dL and non-HDL-C <100 mg/dL.
If goals are not achieved on maximally tolerated statin therapy, additional therapies (e.g., ezetimibe, PCSK9 inhibitors, bempedoic acid) may be necessary.
Consider coronary artery calcium (CAC) test.
Lipid-lowering Therapy
The following groups should receive lipid-lowering therapy regardless of calculated risk:
Established clinical ASCVD.
LDL-C ≥190 mg/dL.
Aged 40–75 with diabetes, chronic kidney disease stage 3 or higher, or HIV on stable combination antiretroviral therapy.
Hypertension
The 2025 AHA/ACC Guideline recommends the following hypertension management (based on 10-year total CVD risk):
BP ≥130/80 mmHg:
Treat if risk estimate ≥7.5%, or if clinical CVD, diabetes, or CKD is present.
If risk estimate is <7.5%, try lifestyle modification for 3–6 months first; start medication if BP remains elevated.
BP ≥140/90 mmHg: Treat all adults regardless of CVD risk estimate.
Risk estimates should be interpreted in the context of:
Patient comorbidities (e.g., diabetes, CKD, obesity).
Risk-enhancing factors (e.g., family history, lipoprotein(a), inflammatory conditions, coronary artery calcium score).
Patient preferences.
Treatment goals.
Based on the 10-year PREVENT-ASCVD estimate for the model that matches the optional predictors entered. Category cutoffs are those reported for the 2026 ACC/AHA dyslipidemia guideline by secondary summaries; confirm against the guideline text before use.
30-year total CVD risk, base model (female)
PREVENT 30-year base model (no optional predictors). Shown for ages 30-79 when no optional predictors are selected.
30-year estimates are advised only for ages 30-59.
Due to the use of age as a time scale, 30-year risk may be overestimated.
30-year total CVD risk, base model (male)
PREVENT 30-year base model (no optional predictors). Shown for ages 30-79 when no optional predictors are selected.
30-year estimates are advised only for ages 30-59.
Due to the use of age as a time scale, 30-year risk may be overestimated.
30-year total CVD risk, base + uACR model (female)
PREVENT 30-year base model with uACR. Shown for ages 30-79 when uACR only is selected.
30-year estimates are advised only for ages 30-59.
Due to the use of age as a time scale, 30-year risk may be overestimated.
30-year total CVD risk, base + uACR model (male)
PREVENT 30-year base model with uACR. Shown for ages 30-79 when uACR only is selected.
30-year estimates are advised only for ages 30-59.
Due to the use of age as a time scale, 30-year risk may be overestimated.
10-year total CVD risk, full model (female)
10-year total CVD risk, full model (male)
30-year total CVD risk, base + HbA1c model (female)
PREVENT 30-year base model with HbA1c. Shown for ages 30-79 when HbA1c only is selected.
30-year estimates are advised only for ages 30-59.
Due to the use of age as a time scale, 30-year risk may be overestimated.
30-year total CVD risk, base + HbA1c model (male)
PREVENT 30-year base model with HbA1c. Shown for ages 30-79 when HbA1c only is selected.
30-year estimates are advised only for ages 30-59.
Due to the use of age as a time scale, 30-year risk may be overestimated.
30-year total CVD risk, base + Social Deprivation Index model (female)
PREVENT 30-year base model with Social Deprivation Index. Shown for ages 30-79 when Social Deprivation Index only is selected.
30-year estimates are advised only for ages 30-59.
Due to the use of age as a time scale, 30-year risk may be overestimated.
30-year total CVD risk, base + Social Deprivation Index model (male)
PREVENT 30-year base model with Social Deprivation Index. Shown for ages 30-79 when Social Deprivation Index only is selected.
30-year estimates are advised only for ages 30-59.
Due to the use of age as a time scale, 30-year risk may be overestimated.
10-year ASCVD risk category: LOW (<3%) - Female Base Model
Risk thresholds used with PREVENT™️ (e.g., 3%–10%) are evolving and not yet fully validated for management decisions.
Primary Prevention
The 2026 ACC/AHA Guideline uses the following risk categories and recommended primary prevention measures (based on 10-year ASCVD risk):
Health behavior counseling.
If LDL-C 160–189 mg/dL or 30-year ASCVD risk is ≥10%, consider moderate-intensity statin therapy.
Lipid-lowering Therapy
The following groups should receive lipid-lowering therapy regardless of calculated risk:
Established clinical ASCVD.
LDL-C ≥190 mg/dL.
Aged 40–75 with diabetes, chronic kidney disease stage 3 or higher, or HIV on stable combination antiretroviral therapy.
Hypertension
The 2025 AHA/ACC Guideline recommends the following hypertension management (based on 10-year total CVD risk):
BP ≥130/80 mmHg:
Treat if risk estimate ≥7.5%, or if clinical CVD, diabetes, or CKD is present.
If risk estimate is <7.5%, try lifestyle modification for 3–6 months first; start medication if BP remains elevated.
BP ≥140/90 mmHg: Treat all adults regardless of CVD risk estimate.
Risk estimates should be interpreted in the context of:
Patient comorbidities (e.g., diabetes, CKD, obesity).
Risk-enhancing factors (e.g., family history, lipoprotein(a), inflammatory conditions, coronary artery calcium score).
Patient preferences.
Treatment goals.
Based on the 10-year PREVENT-ASCVD estimate for the model that matches the optional predictors entered. Category cutoffs are those reported for the 2026 ACC/AHA dyslipidemia guideline by secondary summaries; confirm against the guideline text before use.
30-year heart failure risk, full model (female)
BMI is only used as a predictor for the heart failure risk calculation.
BMIs outside the studied range of <18.5 kg/m² and ≥40.0 kg/m² were excluded in the derivation study.
30-year heart failure risk, full model (male)
BMI is only used as a predictor for the heart failure risk calculation.
BMIs outside the studied range of <18.5 kg/m² and ≥40.0 kg/m² were excluded in the derivation study.
10-year ASCVD risk category: High (≥10%) - Female Base Model
Risk thresholds used with PREVENT™️ (e.g., 3%–10%) are evolving and not yet fully validated for management decisions.
Primary Prevention
The 2026 ACC/AHA Guideline uses the following risk categories and recommended primary prevention measures (based on 10-year ASCVD risk):
Health behavior counseling.
Discuss risk-benefit of pharmacotherapy and weigh risk enhancing factors (e.g., family history, lipoprotein(a), inflammatory conditions, coronary artery calcium score) within a framework of shared decision-making.
Start high-intensity statin therapy, targeting a ≥50% LDL-C reduction with a goal of LDL-C <70 mg/dL and non-HDL-C <100 mg/dL.
If goals are not achieved on maximally tolerated statin therapy, additional therapies (e.g., ezetimibe, PCSK9 inhibitors, bempedoic acid) may be necessary.
Consider coronary artery calcium (CAC) test.
Lipid-lowering Therapy
The following groups should receive lipid-lowering therapy regardless of calculated risk:
Established clinical ASCVD.
LDL-C ≥190 mg/dL.
Aged 40–75 with diabetes, chronic kidney disease stage 3 or higher, or HIV on stable combination antiretroviral therapy.
Hypertension
The 2025 AHA/ACC Guideline recommends the following hypertension management (based on 10-year total CVD risk):
BP ≥130/80 mmHg:
Treat if risk estimate ≥7.5%, or if clinical CVD, diabetes, or CKD is present.
If risk estimate is <7.5%, try lifestyle modification for 3–6 months first; start medication if BP remains elevated.
BP ≥140/90 mmHg: Treat all adults regardless of CVD risk estimate.
Risk estimates should be interpreted in the context of:
Patient comorbidities (e.g., diabetes, CKD, obesity).
Risk-enhancing factors (e.g., family history, lipoprotein(a), inflammatory conditions, coronary artery calcium score).
Patient preferences.
Treatment goals.
Based on the 10-year PREVENT-ASCVD estimate for the model that matches the optional predictors entered. Category cutoffs are those reported for the 2026 ACC/AHA dyslipidemia guideline by secondary summaries; confirm against the guideline text before use.
30-year ASCVD risk is 10% or more (ages 30-59): statin consideration trigger
Based on the 30-year PREVENT-ASCVD estimate for the model that matches the optional predictors entered.
A 30-year risk of 10% or more in adults aged 30-59 is reported by a secondary source as a trigger to consider statin therapy under the 2026 ACC/AHA dyslipidemia guideline; confirm against the guideline text before use.
10-year total CVD risk, base + HbA1c model (female)
10-year total CVD risk, base + HbA1c model (male)
10-year total CVD risk, base + Social Deprivation Index model (female)
10-year total CVD risk, base + Social Deprivation Index model (male)
30-year total CVD risk, full model (female)
PREVENT 30-year full model (uACR, HbA1c and Social Deprivation Index). Shown for ages 30-79 when all three optional predictors are selected.
30-year estimates are advised only for ages 30-59.
Due to the use of age as a time scale, 30-year risk may be overestimated.
30-year total CVD risk, full model (male)
PREVENT 30-year full model (uACR, HbA1c and Social Deprivation Index). Shown for ages 30-79 when all three optional predictors are selected.
30-year estimates are advised only for ages 30-59.
Due to the use of age as a time scale, 30-year risk may be overestimated.
10-year total CVD risk with uACR (female)
10-year total CVD risk with uACR (male)
Body mass index
Calculated from the entered height and weight.
BMI is only used as a predictor for the heart failure risk calculation.
The PREVENT equations were developed in adults with a BMI of approximately 18.5-39.9 kg/m².
BMIs <18.5 kg/m² and ≥40.0 kg/m² were excluded in the derivation study.
Non-HDL cholesterol
10-year total CVD risk (male)
10-year total CVD risk (female)
10-year ASCVD risk category: BORDERLINE (3% to <5%) - Female Base Model
Risk thresholds used with PREVENT™️ (e.g., 3%–10%) are evolving and not yet fully validated for management decisions.
Primary Prevention
The 2026 ACC/AHA Guideline uses the following risk categories and recommended primary prevention measures (based on 10-year ASCVD risk):
Health behavior counseling.
Discuss risk-benefit of pharmacotherapy and weigh risk enhancing factors (e.g., family history, lipoprotein(a), inflammatory conditions, coronary artery calcium score) within a framework of shared decision-making.
If moderate-intensity statin therapy is initiated, target a ≥30% LDL-C reduction with a goal of LDL-C <100 mg/dL and non-HDL-C <130 mg/dL.
Consider coronary artery calcium (CAC) test.
Lipid-lowering Therapy
The following groups should receive lipid-lowering therapy regardless of calculated risk:
Established clinical ASCVD.
LDL-C ≥190 mg/dL.
Aged 40–75 with diabetes, chronic kidney disease stage 3 or higher, or HIV on stable combination antiretroviral therapy.
Hypertension
The 2025 AHA/ACC Guideline recommends the following hypertension management (based on 10-year total CVD risk):
BP ≥130/80 mmHg:
Treat if risk estimate ≥7.5%, or if clinical CVD, diabetes, or CKD is present.
If risk estimate is <7.5%, try lifestyle modification for 3–6 months first; start medication if BP remains elevated.
BP ≥140/90 mmHg: Treat all adults regardless of CVD risk estimate.
Risk estimates should be interpreted in the context of:
Patient comorbidities (e.g., diabetes, CKD, obesity).
Risk-enhancing factors (e.g., family history, lipoprotein(a), inflammatory conditions, coronary artery calcium score).
Patient preferences.
Treatment goals.
Based on the 10-year PREVENT-ASCVD estimate for the model that matches the optional predictors entered. Category cutoffs are those reported for the 2026 ACC/AHA dyslipidemia guideline by secondary summaries; confirm against the guideline text before use.
10-year ASCVD risk category: INTERMEDIATE (5% to <10%) - Female Base Model
Risk thresholds used with PREVENT™️ (e.g., 3%–10%) are evolving and not yet fully validated for management decisions.
Primary Prevention
The 2026 ACC/AHA Guideline uses the following risk categories and recommended primary prevention measures (based on 10-year ASCVD risk):
Health behavior counseling.
Discuss risk-benefit of pharmacotherapy and weigh risk enhancing factors (e.g., family history, lipoprotein(a), inflammatory conditions, coronary artery calcium score) within a framework of shared decision-making.
Start moderate- to high-intensity statin therapy, targeting a ≥30% LDL-C reduction with a goal of LDL-C <100 mg/dL and non-HDL-C <130 mg/dL.
Consider coronary artery calcium (CAC) test.
Lipid-lowering Therapy
The following groups should receive lipid-lowering therapy regardless of calculated risk:
Established clinical ASCVD.
LDL-C ≥190 mg/dL.
Aged 40–75 with diabetes, chronic kidney disease stage 3 or higher, or HIV on stable combination antiretroviral therapy.
Hypertension
The 2025 AHA/ACC Guideline recommends the following hypertension management (based on 10-year total CVD risk):
BP ≥130/80 mmHg:
Treat if risk estimate ≥7.5%, or if clinical CVD, diabetes, or CKD is present.
If risk estimate is <7.5%, try lifestyle modification for 3–6 months first; start medication if BP remains elevated.
BP ≥140/90 mmHg: Treat all adults regardless of CVD risk estimate.
Risk estimates should be interpreted in the context of:
Patient comorbidities (e.g., diabetes, CKD, obesity).
Risk-enhancing factors (e.g., family history, lipoprotein(a), inflammatory conditions, coronary artery calcium score).
Patient preferences.
Treatment goals.
Based on the 10-year PREVENT-ASCVD estimate for the model that matches the optional predictors entered. Category cutoffs are those reported for the 2026 ACC/AHA dyslipidemia guideline by secondary summaries; confirm against the guideline text before use.
Citation
Khan SS, Matsushita K, Sang Y, Ballew SH, Grams ME, Surapaneni A, Blaha MJ, Carson AP, Chang AR, Ciemins E, Go AS, Gutierrez OM, Hwang SJ, Jassal SK, Kovesdy CP, Lloyd-Jones DM, Shlipak MG, Palaniappan LP, Sperling L, Virani SS, Tuttle K, Neeland IJ, Chow SL, Rangaswami J, Pencina MJ, Ndumele CE, Coresh J; Chronic Kidney Disease Prognosis Consortium and the American Heart Association Cardiovascular-Kidney-Metabolic Science Advisory Group. Development and Validation of the American Heart Association's PREVENT Equations. Circulation. 2024 Feb 6;149(6):430-449.
Literature
Khan SS, Matsushita K, Sang Y, Ballew SH, Grams ME, Surapaneni A, Blaha MJ, Carson AP, Chang AR, Ciemins E, Go AS, Gutierrez OM, Hwang SJ, Jassal SK, Kovesdy CP, Lloyd-Jones DM, Shlipak MG, Palaniappan LP, Sperling L, Virani SS, Tuttle K, Neeland IJ, Chow SL, Rangaswami J, Pencina MJ, Ndumele CE, Coresh J; Chronic Kidney Disease Prognosis Consortium and the American Heart Association Cardiovascular-Kidney-Metabolic Science Advisory Group. Development and Validation of the American Heart Association's PREVENT Equations. Circulation. 2024 Feb 6;149(6):430-449. doi: 10.1161/CIRCULATIONAHA.123.067626. Epub 2023 Nov 10. Erratum in: Circulation. 2024 Mar 12;149(11):e956.
https://pubmed.ncbi.nlm.nih.gov/37947085/Fravel MA, Ernst ME, Woods RL, Orchard SG, Ganjali S, Wetmore JB, Reid C, Ryan J, Polkinghorne KR, Wolfe R, Nelson MR, Zoungas S, Zhou Z. Performance of the American Heart Association PREVENT Cardiovascular Risk Equations in Older Adults. Circ Cardiovasc Qual Outcomes. 2025 Jun;18(6):e011719.
https://pubmed.ncbi.nlm.nih.gov/40289804/Mathew, R.O., Khan, S.S., Tuttle, K.R. et al. Performance of the American Heart Association’s PREVENT risk score for cardiovascular risk prediction in a multiethnic population. Nat Med 31, 2655–2662 (2025).
https://www.nature.com/articles/s41591-025-03789-2Zhou H, Zhang Y, Zhou MM, Choi SK, Reynolds K, Harrison TN, Bellows BK, Moran AE, Colantonio LD, Allen NB, Safford MM, An J. Evaluation and Comparison of the PREVENT and Pooled Cohort Equations for 10-Year Atherosclerotic Cardiovascular Risk Prediction. J Am Heart Assoc. 2025 Feb 18;14(4):e039454.
https://pubmed.ncbi.nlm.nih.gov/39921505/Murphy BS, Hershey MS, Huang S, Nam Y, Post WS, McClelland RL, DeFilippis AP. PREVENT Risk Score vs the Pooled Cohort Equations in MESA. JACC Adv. 2025 Jun;4(6 Pt 1):101825.
https://pubmed.ncbi.nlm.nih.gov/40424675/Cho SMJ, Levin M, Chen R, Samarakoon R, Judy R, Hartmann K, Postupaka D, Viscosi V, Farber-Eger E, Fahed AC, Honigberg MC, Patel CJ, Hornsby W, Wells QS, Damrauer SM, Do R, Natarajan P. AHA PREVENT Equations and Cardiovascular Disease Risk in Diverse Health Care Populations. J Am Coll Cardiol. 2025 Jul 22;86(3):181-192.
https://pubmed.ncbi.nlm.nih.gov/40669956/Yan X, Bacong AM, Huang Q, Husby H, Dudum R, Jose P, Palaniappan L, Rodriguez F. Performance of the American Heart Association's PREVENT Equations Among Disaggregated Racial and Ethnic Subgroups. JAMA Cardiol. 2025 Sep 1;10(9):876-885.
https://pubmed.ncbi.nlm.nih.gov/40560603/Gauen AM, Petito LC, Zhang Y, Zhou H, Zhou M, Xia M, Fang M, Reynolds K, Xanthakis V, Safford M, Colantonio LD, Rana JS, Bellows BK, Moran AE, Huang X, Shah NS, Allen NB, An J. PREVENT Equations in Young Adults: Fairness, Calibration, and Performance Across Racial and Ethnic Groups. J Am Coll Cardiol. 2026 Mar 24;87(11):1343-1357.
https://pubmed.ncbi.nlm.nih.gov/41636665/Neuen BL, Major RW, Grams ME, Sang Y, Coresh J, Ballew SH, Surapaneni A, Alencar de Pinho N, Ärnlöv J, Arnott C, Bell S, Berry J, Brenner H, Ciemins E, Chang AR, Cushman M, de Lemos JA, Diaz-Tocados JM, Farjat AE, Fletcher RA, Gansevoort RT, Heerspink HJL, Herrington WG, Hong C, Horwitz EJ, Hwang SJ, Jassal SK, Kalra PA, Katz R, Khan SS, Kovesdy CP, Kronenberg F, Lees JS, Lloyd-Jones DM, Mill JG, Naimark DMJ, Ndumele C, Polkinghorne KR, Psaty BM, Schloemer P, Shlipak MG, Shrestha P, Song Z, Staplin N, Steubl D, Vart P, Visseren FLJ, Woodward M, Yamagishi K, Young BA, Sabanayagam C, Valdivielso JM; CKD Prognosis Consortium investigators. Multinational validation of the PREVENT and SCORE2 cardiovascular risk equations across 6.4 million individuals. Nat Med. 2026 Jul;32(7):2629-2638.
https://pubmed.ncbi.nlm.nih.gov/42086979/Writing Committee Members*; Jones DW, Ferdinand KC, Taler SJ, Johnson HM, Shimbo D, Abdalla M, Altieri MM, Bansal N, Bello NA, Bress AP, Carter J, Cohen JB, Collins KJ, Commodore-Mensah Y, Davis LL, Egan B, Khan SS, Lloyd-Jones DM, Melnyk BM, Mistry EA, Ogunniyi MO, Schott SL, Smith SC Jr, Talbot AW, Vongpatanasin W, Watson KE, Whelton PK, Williamson JD. 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Hypertension. 2025 Oct;82(10):e212-e316.
https://pubmed.ncbi.nlm.nih.gov/40811516/Blumenthal RS, Morris PB, Gaudino M, Johnson HM, Anderson TS, Bittner VA, Blankstein R, Brewer LC, Cho L, de Ferranti SD, Gianos E, Gluckman TJ, Gradney KF, Isiadinso I, Lloyd-Jones DM, Marrs JC, Martin SS, McLain KH, Mehta LS, Mora S, Mulugeta WM, Natarajan P, Navar AM, Orringer CE, Polonsky TS, Reynolds HR, Saseen JJ, Shapiro MD, Soffer DE, Tynes SA, Villavaso CD, Virani SS, Wilkins JT. 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2026 May 19;87(19):2624-2757.
https://pubmed.ncbi.nlm.nih.gov/41824590/Khan SS, Coresh J, Pencina MJ, Ndumele CE, Rangaswami J, Chow SL, Palaniappan LP, Sperling LS, Virani SS, Ho JE, Neeland IJ, Tuttle KR, Rajgopal Singh R, Elkind MSV, Lloyd-Jones DM; American Heart Association. Novel Prediction Equations for Absolute Risk Assessment of Total Cardiovascular Disease Incorporating Cardiovascular-Kidney-Metabolic Health: A Scientific Statement From the American Heart Association. Circulation. 2023 Dec 12;148(24):1982-2004.
https://pubmed.ncbi.nlm.nih.gov/37947094/Ndumele CE, Rangaswami J, Chow SL, Neeland IJ, Tuttle KR, Khan SS, Coresh J, Mathew RO, Baker-Smith CM, Carnethon MR, Despres JP, Ho JE, Joseph JJ, Kernan WN, Khera A, Kosiborod MN, Lekavich CL, Lewis EF, Lo KB, Ozkan B, Palaniappan LP, Patel SS, Pencina MJ, Powell-Wiley TM, Sperling LS, Virani SS, Wright JT, Rajgopal Singh R, Elkind MSV; American Heart Association. Cardiovascular-Kidney-Metabolic Health: A Presidential Advisory From the American Heart Association. Circulation. 2023 Nov 14;148(20):1606-1635.
https://pubmed.ncbi.nlm.nih.gov/37807924/Diao JA, Shi I, Murthy VL, et al. Projected Changes in Statin and Antihypertensive Therapy Eligibility With the AHA PREVENT Cardiovascular Risk Equations. JAMA. 2024;332(12):989–1000.
https://jamanetwork.com/journals/jama/fullarticle/2821624
- Creator
- Provided by
EVAL Foundation
- Contributor · Reviewer
Jennifer Glen, DNP, FNP-BCEVAL Health, Chief Medical Officer EVAL Foundation
Related evaluations
Also from EVAL Foundation
Alcohol Use Disorders Identification Test - C (AUDIT-C)
A 3-item tool to screen for unhealthy alcohol use in patients who may not be alcohol-dependent.
Dr. Katharine Bradley, MD, MPHAlcohol Use Disorders Identification Test (AUDIT)
A 10-item tool to screen for hazardous alcohol use, harmful use, and alcohol dependence.
World Health Organization Collaborative ProjectAmerican Shoulder and Elbow Surgeons (ASES) Shoulder Score
15-item assessment of shoulder pain and functional limitations in activities of daily living.
Dr. Robin R. Richards, MD, FRCSC, FAAOS, FAOABehavioral Activity Rating Scale (BARS)
A 1-item rating scale to quantify a patient's level of agitation in acute care or psychiatric settings.
CAGE Alcohol Questionnaire
4-item questionnaire that can indicate potential problems with alcohol use.
Drug Abuse Screening Test (DAST-10)
A patient self-report questionnaire to screen for problematic drug use (excluding alcohol/tobacco).
Dr. Harvey A. Skinner, Ph.D.Foot and Ankle Ability Measure (FAAM)
Assesses functional limitations and disability related to foot and ankle conditions in daily activities and sports.
Dr. Jesse Van Swearingen, PhD, PT, FAPTAFoot and Ankle Disability Index (FADI)
Assess functional limitations of those with a variety of foot and ankle conditions
Dr. RobRoy Martin, PhD, PT, CSCS